Collaboration revenue increased to 23017000 in the fourth quarter of 2025, while net loss narrowed to 95786000 compared to 128898000 in the prior year period, driven by lower operating expenses.

Intellia Therapeutics reported a significant reduction in net loss for Q2 2025, decreasing to $101.3 million from $147.0 million in Q2 2024. Collaboration revenue increased, and operating expenses saw a notable decrease, primarily driven by lower R&D and G&A expenses. The company ended the quarter with a strong cash position, expected to fund operations into the first half of 2027.

Intellia Therapeutics reported a net loss of $114.3 million for the first quarter of 2025, compared to a net loss of $107.4 million in the same period last year. Collaboration revenue decreased to $16.6 million from $28.9 million, primarily due to a decrease in the AvenCell license and collaboration agreement. The company ended the quarter with $707.1 million in cash, cash equivalents, and marketable securities, and expects to fund operations into the first half of 2027.

Intellia Therapeutics reported its Q4 and full-year 2024 financial results, highlighting the dosing of the first patient in the global Phase 3 HAELO study for NTLA-2002 and the continued progress of the Phase 3 MAGNITUDE trial for nexiguran ziclumeran. The company ended the year with approximately $862 million in cash, cash equivalents, and marketable securities.

Intellia Therapeutics reported progress in advancing its pipeline of CRISPR-based gene editing therapies, including the initiation of the HAELO Phase 3 study and continued strong enrollment in the MAGNITUDE Phase 3 study. The company ended the quarter with $944.7 million in cash, cash equivalents and marketable securities.